Abstract
Real World Evidence (RWE) use in both safety and effectiveness evaluations is recognized by EMA and FDA. There is extensive evidence of RWE use in oncology, but studies focused on Pharmaceutical Consultation (PC) and breast cancer (BC) are lacking. CDK4/6 inhibitors are novel oral agents in hormone receptor-positive metastatic breast cancer (MBC). The objective of this study was to evaluate RWE of these agents in MBC using PC data.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
